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Abstract
Cell surface glycoconjugates present alterations of their structures in chronic diseases and
distinct oligosaccharide epitopes have been associated with cancer. Among them, truncat-
ed glycans present terminal non-reducing β-N-acetylglucosamine (GlcNAc) residues that
are rare on healthy tissues. Lectins from unconventional sources such as fungi or algi pro-
vide novel markers that bind specifically to such epitopes, but their availability may be chal-
lenging. A GlcNAc-binding lectin from the fruiting body of the fungus Psathyrella velutina
(PVL) has been produced in good yield in bacterial culture. A strong specificity for terminal
GlcNAc residues was evidenced by glycan array. Affinity values obtained by microcalorime-
try and surface plasmon resonance demonstrated a micromolar affinity for GlcNAcβ1-3Gal
epitopes and for biantennary N-glycans with GlcNAcβ1-2Man capped branches. Crystal
structure of PVL complexed with GlcNAcβ1-3Gal established the structural basis of the
specificity. Labeling of several types of cancer cells and use of inhibitors of glycan metabo-
lism indicated that rPVL binds to terminal GlcNAc but also to sialic acid (Neu5Ac). Analysis
of glycosyltransferase expression confirmed the higher amount of GlcNAc present on can-
cer cells. rPVL binding is specific to cancer tissue and weak or no labeling is observed for
healthy ones, except for stomach glands that present unique αGlcNAc-presenting mucins.
In lung, breast and colon carcinomas, a clear delineation could be observed between can-
cer regions and surrounding healthy tissues. PVL is therefore a useful tool for labeling aga-
lacto-glycans in cancer or other diseases.
Introduction
Changes in cell surface glycosylation are known to be associated with a large number of chronic
diseases and the cancer glycans represent a very promising field for biomarker discovery [1–3].
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Correlation of inflammation or metastasis with overexpression of sialylated and fucosylated
epitopes, such as sialyl Lewis x has been the subject of intensive research. However, in other
cases, the very active metabolism and divison of cancer cells can result in the abnormal expo-
sure of cryptic epitopes. This internal part of glycoconjugates, that would have been decorated
by other monosaccharides in normal cells, may therefore be exposed on the cell surface and be-
come available for detection by antibodies or lectins [4].
N-acetylglucosamine (GlcNAc) is a carbohydrate residue that is present in the inner part of
N-glycans, as the core chitobiose linked to asparagine residue and more rarely as β1–4 linked
to the core branched mannose in bisected N-glycans. GlcNAc is also present in the branches of
these glycoconjugates, either β1-2-linked to mannose (Man) on the trimannose core or β1-
3-linked to galactose (Gal) as part of polylactosamine extended branches (Fig 1A). Neverthe-
less, due to the activity of galactosyltransferases and sialyltransferases, these GlcNAc residues
are not in terminal positions in normal tissues. Similarly glycosphingolipids contain
GlcNAcβ1–3 or β1–6 linked to Gal but not in exposed terminal positions. The epitopes are
similar in mucins with Gal, sialic acid (Neu5Ac) or fucose (Fuc) residues capping the terminal
epitopes. The only exception is a rare epitope consisting of α1–4 linked GlcNAc-terminated
mucins from glandular mucous cells in the stomach [5] (Fig 1A).
The occurrence of aberrant βGlcNAc-terminating epitopes has been observed in a limited
number of cancers, including human leukemia cells [6]. IgGs with truncated N-glycans have
been reported in the serum of prostate cancer patients [7]. Altered mucins with terminal
GlcNAc motifs were proposed to form the Tk epitope, a colon tumor associated antigen [8].
The most precise characterization of the alterations of glycosylation with exposure of internal
GlcNAc was performed by glycome analysis of different carcinoma, pointing to the occurrence
of short truncated N-glycans terminated by GlcNAβ1-2Man on both antenna and of GlcNAc-
terminated linear and branched glycosphingolipids, particularly in lung small-cell carcinoma
and adenocarcinoma, but also in kidney, breast and ovary carcinoma [9] (Fig 1A).
Lectins, generally derived from plants, have been demonstrated to be very efficient for de-
tecting aberrant glycosylation in biological samples. A new technology is the use of lectin arrays
that can contain lectins with large spectra of specificity and therefore characterize variation of
glycosylation [10]. The use of lectins extracted from natural organisms may be time-consuming
and may generate problems of contamination or variations between batches. Therefore, recom-
binant lectin technology is starting to be developed [11]. Lectins that are classically used for
GlcNAc-binding are extracted from plants such as wheat (WGA), tomato (SLT) and Griffonia
simplicifolia (GSL-II). A new GlcNAc-specific lectin (PVL) was purified from the fruiting bod-
ies and mycelium of a fungus, Psathyrella velutina [12] and then structurally characterized
[13]. A closely related protein, lectin 2 from mushroom Agrocybe aegerita (AAL-2) has been re-
cently cloned and demonstrated to bind to hepatoma cells [14]. The PVL structure presents a
novel fold among lectins, with seven β-sheets arranged in a β-propeller fold. The lectin there-
fore adopts a donut shape with six GlcNAc binding sites, and is expected to present strong
avidity for cell surfaces presenting high density of terminal GlcNAc residues.
The aim of the present work was to produce a recombinant form of PVL and to characterize
its fine specificity towards the different GlcNAc-terminated epitopes that could be present on
pathology-related truncated forms of human glycoconjugates. The avidity of the lectin for
GlcNAc-decorated surface was evaluated on arrays. Finally, the ability of the lectin to label can-
cer cells and carcinoma tissues was also described.
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Fig 1. Representation of glycoconjugates and binding of rPVL to glycans on chips. A. Examples of normal and truncated oligosaccharides that can be
found on normal or cancer tissues. Coding for schematic representation of monosaccharides is in the lower part of the figure. The heptasaccharide used in
binding experiments is indicated as “hepta”. B. Synthesis of heptasaccharide azide 2 corresponding to oligosaccharide “hepta” in panel A.
doi:10.1371/journal.pone.0128190.g001
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Materials and Methods
Material
GlcNAc has been purchased from Sigma-Aldrich. Disaccharide GlcNAcβ1-3Gal, lacto-N-tetra-
ose (Galβ1-3GlcNAcβ1-3Galβ1-4Glc), lacto-N-triose (GlcNAcβ1-3Galβ1-4Glc) chitobiose
(GlcNAcβ1-4GlcNAc), chitopentaose (GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ1-
4GlcNAc) have been purchased from Elicityl (Crolles, France). Sialidase from Clostridium per-
fringens has been purchased from Sigma-Aldrich (ref. N2876) or New England Biolabs (Ipswich,
MA). ß-D-N-Acetyl-hexosaminidasef from Streptomyces plicatus was purchased from New En-
gland Biloabs. The biotin-labeled sialic acid-specific lectin MAHwas purchased from Vector
Labs (Burlingame, CA)
Synthesis of N-glycan 2
Nonasaccharide azide 1 (Fig 1B) was prepared from egg yolk followed by enzymatic hydrolysis
and azidation [15, 16]. 5.1 mg (3.1 μmol) of nonasaccharide 1 were disolved in 203 μl of phos-
phate buffer (100 mM, pH 6.8, 1 mM MgCl2). 10 units of lyophilized β-galactosidase (EC
3.2.1.23) were added to the solution. The mixture was incubated at 37°C for 3 days (TLC:
2-propanol, 1 M ammonium acetate, 2:1). After lyophilization, the residue was purified by gel
filtration (Superdex 30, 1.6 x 60 cm, 0.1 M NH4HCO3, 0.9 ml min
-1). The peak, eluting at
86 min, was lyophilized and desalted by gel filtration (Sephadex G-25, 2.5 x 15.5 cm, 5% etha-
nol in water, 0.6 ml min-1). The peak, eluting at 75 min, was lyophilized yielding 2.9 mg
(2.2 μmol) of heptasaccharide 2 (70%). [α]D
22 = -9.0 (c = 0.5, H2O). The purity was confirmed
by 360 MHz 1H NMR in D2O (S1 Fig)
1H-NMR (360 MHz, D2O): δ = 5.03 (d, J1,2< 1 Hz, 1H,
H-14), 4.83 (d, J1,2< 1 Hz, 1H, H-1
4´), 4.68–4.64 (m, 2H, H-11, H-13), 4.53 (d, J1,2 = 7.7 Hz,
1H, H-12), 4.47 (d, J1,2 = 8.3 Hz, 2H, H-1
5, H-15’), 4.18–4.15 (m, 1H, H-23), 4.12–4.09 (m, 1H,
H-24), 4.04–4.01 (m, 1H, H-24’), 1.99 (s, 3H, NAc), 1.97 (s, 9H, NAc). ESI-MS: m/z calcd for
C50H83N7O35: 1341.49; found 1342.62 (M+H)
+, 1365.86 (M+Na)+
Production of recombinant PVL
A nucleotide sequence coding for the peptide sequence of lectin from fruiting body of mush-
room P. velutina (GenBank, accession number DQ232759) [13] supplemented at N-terminal
position with the amino-acids MSVVVIS was synthesized after codon optimization for expres-
sion in Escherichia coli (GenScript, Piscataway, NJ). It was introduced into the expression vec-
tor pET25b using NdeI and XhoI restriction sites. The pET25-rPVL vector was transformed
into E. coli BL21(DE3) (Novagen), and cells harboring pET25-rPVL plasmid were grown in LB
broth containing 100 μg ml-1 ampicillin at 37°C until A600 reached 0.7. The cells were then
cultured for 16 h after addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside. After centri-
fugation (7000 x g for 15 min), bacteria were resuspended in equilibration buffer (20 mM Tris/
HCl, pH 7.5, 150 mMNaCl) and broken by cell disruption at a pressure of 1.7 kilobars (Con-
stant systems Ltd). After centrifugation (50000 x g, 30 min at 4°C) and filtration, affinity chro-
matography on a GlcNAc-agarose column (EY laboratories inc.) was performed on the
supernatant. rPVL was allowed to bind to immobilized GlcNAc in equilibration buffer, and
after washing (20 mMTris/HCl pH 7.5, 1 M NaCl), it was eluted with 200 mM of free GlcNAc
in equilibration buffer. Purified protein was dialyzed extensively against ultrapure water for 7
days, freeze-dried, and stored at 4°C.
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Glycan array
Purified rPVL were labeled with Alexa Fluor 488 (Invitrogen) according to the manufacturer’s
instructions and repurified on a D-Salt polyacrylamide desalting column (Pierce). Alexa-la-
beled rPVL was used for glycan array screening with the standard procedure of the Protein-
Glycan Interaction Core (H) of the Consortium for Functional Glycomics.
Thermal shift analysis
Thermal shift assays were performed using a Mini Opticon, Real Time PCR machine (Bio-Rad
Laboratories) with 0.5 mg ml-1 of protein diluted in 100 mMNaCl, 20 mM Tris pH 7.5,
100 μMCaCl2, with or without oligosaccharide in a total reaction volume of 25 μl. SYPRO Or-
ange (Molecular Probes, CA) was used as a fluorescent probe detected at 530 nm. The tempera-
ture was raised using 1°C/minute steps from 25°C to 100°C and fluorescence readings were
taken at each interval. A positive ΔTm value indicates that the ligand stabilizes the protein
from denaturation, and therefore binds to the protein. A minimum of two independent mea-
surements were performed for each condition
Microcalorimetry
Recombinant lyophilized rPVL was dissolved in buffer (20 mM Tris/HCl, pH 7.5, NaCl 150
mM, 100 μMCaCl2) and degassed. The protein concentration was checked by measuring A280
by using a theoretical molar extinction coefficient of 65,890 M-1 cm-1. Carbohydrate ligands
were dissolved in the same buffer, degassed, and loaded in the injection syringe. ITC was per-
formed with a ITC200 microcalorimeter (GE Healthcare). The rPVL solution was placed in a
200 μl sample cell at 25°C. Titration was performed with 20 injections of 2 μl carbohydrate li-
gands every 120 s. The experimental data were fitted to a theoretical titration curve using Ori-
gin software supplied by GE Healthcare, with ΔH (enthalpy change), Ka (association constant)
and n (number of binding sites per monomer) as adjustable parameters. Free energy change
(ΔG) and entropy contributions (TΔS) were derived from the equation ΔG = ΔH – TΔS =—RT
ln Ka (with T as the absolute temperature and R = 8.314 J mol-1 K-1). Two independent titra-
tions were performed for each tested ligand.
Surface plasmon resonance
All SPR experiments were performed on a Biacore X100 instrument (GE Healthcare) at 25°C
in HBS (10 mMHepes/NaOH, pH 7.5, 150 mMNaCl, 0.05% Tween 20) supplemented with
100 μM of CaCl2 at a flow rate of 30 μl min
-1. Binding was measured as resonance units over
time after blank subtraction, and data were then evaluated by using the Biacore X100 evalua-
tion software, version 2.0. Dissociation constants were determined by plotting response at equi-
librium (Req, 10 s before the end of injection) against analyte concentration. For protein
coated chip, 3500 resonance units of rPVL (100 μg ml-1, 10 mM acetate buffer pH 6.2) have
been immobilized on flow channel 2 of a research grade CM5 chip using standard amine cou-
pling procedures. Flow channel 1 has been activated/deactivated. Experiments consist of injec-
tion (association 360 s, dissociation 400 s) of various concentrations of oligosaccharides (2 fold
cascade dilutions, from 0 to 10 μM) on both channels.
Protein crystallography
Crystals of rPVL complexed with GlcNAcβ1-3Gal were obtained by the hanging drop at 20°C.
Lyophilized protein was dissolved at 2.5 mg ml-1 in 10 mMHepes/NaOH buffer, pH 7.5, NaCl
150 mM, 100 μMCaCl2 and incubated with 1 mMGlcNAcβ1-3Gal during 1h at room
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temperature prior to co-crystallization. One big rectangular-like crystal was obtained from
20% PEG3350, 0.2 M Sodium Formate and 0.1 M diammonium phosphate after several
months. One piece was directly mounted in a cryoloop and flash-freezed in liquid nitrogen.
Diffraction data were collected at 100 K at the European Synchrotron Radiation Facility (Gre-
noble, France) at station BM30A using a ADSC Q315r CCD detector [17]. The data were pro-
cessed using XDS [18]. All further computing was performed using the CCP4 suite [19] Data
quality statistics are summarized in S1 Table. The molecular replacement technique was used
to solve the structure with PHASER [20] and the coordinates of the native PVL (Protein Data
Bank code 2C4D) [13]. The structure was refined by restrained maximum likelihood refine-
ment using REFMAC 5.8 [21] iterated with manual rebuilding in Coot [22]. Incorporation of
the ligand was performed after inspection of the mFo-DFc weighted maps. Water molecules,
introduced automatically using Coot, were inspected manually. The stereochemical quality of
the models was assessed with the programMolprobity [23], and coordinates were deposited in
the Protein Data Bank under codes 4UP4.
Cells lines
Human non-small cell lung cancer (NSCLC) (H358, A549, H441 and H322), bronchial epithe-
lial (HBEC-3KT), breast cancer (MCF-7, MDA-MB-231), ovarian cancer (OVCAR3), prostate
cancer (DU-145), skin squamous cell carcinoma (A431), melanoma (A375, Colo829 and
SKMel28), and colon cancer (HT-29) cell lines were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). The M119 melanoma cell line was a gift from Dr Nathalie
Labarrière (Inserm U892, Nantes, France). The cells were maintained in RPMI-1640 medium
(Gibco, Cergy Pontoise, France), except MDA-MB-231 and HT-29, which were grown in
DMEM 4.5 g l-1 glucose (Gibco), and HBEC-3KT, which were maintained in Keratinocyte-
SFM medium (Gibco). All the culture media were supplemented with 10% heat-inactivated
fetal bovine serum (5% for MDA-MB-231) and cells were kept in a humidified atmosphere
with 5% CO2, at 37°C.
Flow cytometry
Cells were trypsinized, aliquoted, then washed twice in PBS (with Ca2+ and Mg2+). After incu-
bation with rPVL-Alexa488 (5 and 10 μg ml-1), cells were washed twice and analysis was per-
formed on an Accuri C6 flow cytometer using the CFlow-Plus Software (BD Biosciences).
Alternatively, biotinylated rPVL or MAH were used, followed by Streptavidin-phycoerythrin
(BD) and analysis was performed on a FACSCalibur with the Cellquest software (BD). Where
indicated, cells were pre-teated with sialidase (Sigma) or ß-D-N-acetyl-hexosaminidase for 4h
at 37°C.
Inhibition of glycosylation
A549 cells were seeded in 6 well plates and treated with different glycosylation inhibitors: a
fucosyl transferase inhibitor, 2-fluoro-peracetyl fucose (2FF) and a sialyl-transferase inhibitor,
3-fluoro-peracetyl-neuraminic acid (3F-Neu5Ac) that have been described recently [24]. Treat-
ment was performed for 4 days with 400 μM and 100 μM of 2FF and 3F-Neu5Ac respectively.
Medium was replaced and inhibitors were added again after 2 days.
In order to investigate the type of glycosylated ligands that are recognized by rPVL, we used
Kifunensin (Sigma) which blocks ER α-mannosidase I and consequently the processing of N-
glycans; benzyl-2 acetamido-2 deoxy-alpha-D-galactopyranoside (Benzyl-GalNAc; Sigma)
which blocks the O-glycosylation process and 1R,2R-(+)-1-phenyl-2-palmitoylamino-3-N-
morpholine-1-propanol (PPMP; Avanti Polar Lipids, Alabaster, USA) which inhibits synthesis
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of glycolipids. Cells were treated with 5 μMKifunensin for 4 days as above. For Benzyl-GalNAc
and PPMP, cells were left in contact with the inhibitors, at 6 mM and 10 μM respectively, over
a 24h period, then the medium was changed and the cells were incubated for 1 more day before
analysis. As 2FF, 3F-Neu5Ac and PPMP are diluted in DMSO, pure DMSO was added to the
medium of control wells in order to have the same DMSO concentration in each well.
Immunofluorescence analysis
Cells were seeded into 4-chamber culture slides (4x104 cells per chamber). After 24h, cells were
washed with ice-cold PBS and fixed with 2% paraformaldehyde for 10 min at 4°C. Before and
after incubation with 1% BSA/PBS (w/v), cells were washed with cold PBS three times for 5
min each. Cells were then subjected to immunofluorescence staining with rPVL-Alexa488 for
1h at room temperature and then washed with cold PBS three times for 3 min each. Cells were
examined using a BX41 microscope equipped with a DP-70 digital camera system (Olympus,
Tokyo, Japan) and a pseudo-confocal microscope ApoTome equipped with AxioCamMRm
(N/B).
Tissue sections
Ethanol-fixed human trachea, esophagus, duodenal junction, jejunum, colon, pancreas, liver,
ovary, uterus and vagina samples were obtained from organ donors. 18 tissue samples from 10
different individuals were used to prepare a tissue microarray (TMA) of healthy tissues. Etha-
nol-fixed colorectal tumor sections were obtained after cancer surgery. Formalin-fixed paraf-
fin-embedded human NSCLC samples (n = 3 squamous cell carcinomas, n = 3
adenocarcinomas) were also obtained. A breast tumor and a lung tumor TMA (formalin-fixed;
40 tumors, 10 paired metastasis and 10 paired adjacent “normal” tissue) were bought from
SuperBiochip (Seoul, South Korea). Formalin-fixed canine mammary tumors were obtained
from "laboratory of animal histopathology of the Nantes Veterinary School, ONIRIS) Immu-
nostaining analysis was performed on 3-μm-thick tissue sections.
Histochemistry
The tissue sections were deparaffinized, then endogenous peroxidases were blocked by incubat-
ing the sections with PBS containing 3% hydrogen peroxide (v/v), for 5 mn. The sections were
then blocked with BSA 5% (w/v) for 30 min at room temperature, followed by incubation with
0,7–1 μg ml-1 biotinylated rPVL 1h at room temperature (Ethanol-fixed sections) or 2 μg ml-1
of biotinylated rPVL in PBS at 4°C for 18h (for formalin-fixed sections). After washing the sec-
tions twice with PBS, an indirect biotin-streptavidin system and DAB (Ventana Medical Sys-
tems) or AEC (Vector laboratories) detection kits were used according to the manufacturer’s
instructions. The developed slides were washed twice with PBS and counterstained with hema-
toxylin. After washing with water, the sections were dehydrated and mounted. Sections were
observed under a BX41 microscope equipped with a DP-70 digital camera system (Olympus,
Tokyo, Japan) or imaged with a NanoZoomer slide-scanner (Hamamatsu, Hamamatsu City).
For treatment with glycosidases, sections were incubated (after deparaffination and hydro-
gen peroxide blocking) with 50 U of sialidase (New England Biolabs) or 25 U of ß-D-N-acetyl-
hexosaminidase for 2 hours at 37°C. Fresh enzymes were then added and the slides were fur-
ther incubated overnight at 37°C. Control slides were prepared in parallel with the correspond-
ing enzyme buffers (Sodium Citrate pH 6 and 4.5 respectively). After overnight incubation, the
slides were washed twice in PBS, blocked with PBS-5% BSA (w/v), stained with rPVL and im-
aged as described above.
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Ethics statements
All the human ethanol-fixed tissues tissues were collected and stored before the law 88–138 of
December 20, 1988 concerning resection of human tissues after death for scientific investiga-
tions. For this reason, no approval by a Research Ethics Committee applies. The samples were
obtained from the Nantes University Hospital Center for Biological Resources (http://relib.fr),
under the Cancerology program approved by the ministry of research (approval DC-2011-
1399). Tissue banking and research conduct of the formalin-fixed human tissues were ap-
proved by the ministry of research (approval AC-2010-1129) and by the regional Institutional
Review Board Comité de Protection de Personnes (CPP) 5—Sud Est (regional board). All pa-
tients enrolled in this trial provided written informed consent. These specific samples were pre-
viously used as described in literature [25, 26]. Regarding the Tissue MicroArrays obtained
from Superbiochips Laboratories Ltd (Seoul, Korea), the company certifies that the “human
material have been removed or collected with the donor’s prior consent and that no payment
whatsoever has been made to the latter”. Formalin-fixed tissues from canine breast tumors
were obtained from "laboratory of animal histopathology” of the Nantes Veterinary School
(ONIRIS). Cases coming from the Pathology Laboratory of the Veterinary Teaching Hospital
of Oniris were used in this study. The owners’ written consent and approval from the Oniris
College of Veterinary Medicine local Animal Welfare Committee were obtained prior to inclu-
sion. The animal care and used protocol adhered to the European Directive number 2010/063
and to the national French regulation (Décret n°2013–118 du 1er février 2013 relatif à la pro-
tection des animaux utilisés à des fins scientifiques).
Results
Production and characterisation of rPVL
PVL has been produced recombinantly (rPVL) in E. coli and purified in one step on a GlcNAc-
agarose column with a final yield of 1 mg l-1 of culture. When assayed on rabbit erythrocytes,
the lectin displayed strong hemagglutination activity down to concentration of 2.3 nM. The re-
combinant protein is stable and demonstrates a denaturation temperature of 56°C by thermal
shift analysis (S2 Fig). Further stabilization of rPVL can be obtained in the presence of
GlcNAc-containing ligands like GlcNAcβ1-3Gal or chitobiose, with a Tm of 60°C for both, but
not in the presence of non-binding carbohydrate such as galactose and sucrose, confirming the
GlcNAc binding activity.
rPVL is specific for oligosaccharides with terminating GlcNAc residues
The specificity of recombinant PVL was assayed on the Mammalian Printed Array version 5.1
with 610 glycans, mostly from mammalian origin. The rPVL concentration was varying from
0.2 mg ml-1 to 0.2 μg ml-1 and the four datasets are available from the CFG site with prim-
screen_codes 5693, 5695, 5696 and 4697 (http://www.functionalglycomics.org). The fluores-
cence signal was excellent and the lowest concentration was sufficient for the determination
of the strong preference for oligosaccharides carrying a GlcNAc at their non-reducing end
(Fig 2).
The lectin bound efficiently to GlcNAc present in two different positions in truncated N-
glycans: GlcNAcβ1-2Man on the core pentasaccharides and even more strongly on GlcNAcβ1-
3Gal on antenna that are extended by polylactosamine motifs. Because of multivalency effect,
the signal was maximal for multiantennary structures (2 to 5 antenna) with lactosamine re-
peats, the occurrence of which is related to cancer progression [27]. Polylactosamine bi- or
multi-antennary N-glycans with terminal GlcNAcβ1-3Gal were bound with fluorescence
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signals higher than 1500 RU, while the ones with terminal Galβ1-4GlcNAc are in the back-
ground noise, below 150 RU. No binding is observed to the GlcNAcβ1-4Man motif present in
bisected N-glycans, but the presence of this bisecting GlcNAc does not hinder the binding of
PVL to neighboring GlcNAc-terminated antenna. The lectin also bound to mucin motifs that
bear βGlcNAc on position 3 and 6 of a GalNAc residue (type 4). It bound only weakly to the
chitobiose motif (GlcNAcβ1-4GlcNAc) of chitin. The lectin is not selective for the anomeric
configuration of the GlcNAc and several oligosaccharides with terminal αGlcNAc residues
were also labeled. Such epitopes are present in human heparan sulfate (GlcNAc α1-4IdoA) and
in mucins of gastric glands (GlcNAc α1-4Gal) [5], but also in class III mucin of carcinoma tis-
sues that express a gastric phenotype [28]. The glycan array contains a variety of oligosaccha-
rides with terminal GalNAc but PVL binding was observed only to the disaccharide
GalNAcβ1-3GalNAc (#97) with minor intensity.
Since immobilized wild-type PVL was reported to bind to sialylated glycoproteins [29], the
binding to oligosaccharides with sialylated structures was checked. Indeed a weak binding may
be observed for biantennary N-glycans with terminating Neu5Acα2-3Gal epitopes (#603 in Fig
2). The level of fluorescence was close to the noise level (12% of maxium). Nevertheless, when
checking the glycan array data obtained with higher concentration of PVL (0.1 mg ml-1), the
binding to sialyl-oligosaccharides became clearly visible.
The affinity of rPVL for various GlcNAc-containing oligosaccharides was tested for both
free and surface bound proteins using titration microcalorimetry and surface plasmon reso-
nance, respectively (Table 1 and S3 Fig). The affinity for GlcNAc is in the same range as that
previously measured by ITC with native PVL isolated from mushroom (Kd200 μM) [13].
Quantitative measurements confirmed a stronger affinity for GlcNAcβ1-3Gal-terminated
structures than for GlcNAc and chitooligosaccharides, with dissociation constant of about
70 μM for the trisaccharide lacto-N-triose. A good agreement was observed between values
measured by both methods. Only the N-glycan heptasaccharide presenting two terminal
GlcNAcβ1-2Man epitopes showed stronger affinity for rPVL in solution (Kd of 34 μM) than
Fig 2. Direct fluorescence measurement obtained with Alexa Fluor 488 labeled rPVL (0.2 μl ml-1) on the Mammalian Printed Array version 5.1 from
the Consortium for Functional Glycomics. Each hit has been colored according to the terminal disaccharide. Representative oligosaccharides have been
schematically displayed. Peaks indicated by a * correspond to minor labeling of sialic-acid terminated oligosaccharides. The full list of oligosaccharides with
fluorescence intensities is available from CFG web site (http://www.functionalglycomics.org).
doi:10.1371/journal.pone.0128190.g002
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on SPR chip. This may be due to the bivalent character of this particular interaction that may
be more easily established with the protein in solution than fixed on a chip. The binding of
both terminal GlcNAc residues of the biantennary heptasaccharide was confirmed by compar-
ing the stoichiometry of linear GlcNAcβ1-3Gal (five ligands per rPVL) and of biantennary hep-
tasaccharide (two ligands per rPVL). The thermodynamics of binding was also different since
the biantennary glycan is the only one to present a favorable entropy of binding (Table 1), that
could be explained by the preorientation of the two GlcNAc residues in space.
Crystal structure of rPVL/disaccharide
rPVL was crystallized in complex with GlcNAcβ1-3Gal, the disaccharide that caps truncated
polylactosamine N-glycans. The structure was solved at 1.95 Ǻ resolution (S1 Table) and dis-
played the expected seven-bladed β-propeller fold (Fig 3). Two β-propellers are present in the
asymmetric unit, but since they are very similar, only chain A is described below. The overall
structure of the recombinant protein was very similar to the one described previously for wild-
type PVL [13]. The main difference was the presence of an additional calcium ion since rPVL
presents calcium in three loops. Clear electron density was observed for the GlcNAcβ1-3Gal in
five binding sites while site 2 was occupied only by a GlcNAc residue (Fig 3A and 3B).
In each of the six binding sites, the terminal GlcNAc was in the same orientation as in the
PVL/GlcNAc complex, and established the same network of hydrogen bonds. The galactose
residue interacted in a shallow area near the GlcNAc binding site (Fig 3C). The interaction of
the galactose residue were not very strong, and varied from one site to the other. Nevertheless,
one common feature was the involvement of a water molecule that was present in all the sites
and bridges the disaccharides (atoms O-acetyl of GlcNAc and O-4 of galactose) with backbone
nitrogen atoms of the protein and with side chains of the conserved aromatic rings (Trp or
Tyr) that stacked against the GlcNAc surface (Fig 3D). This water molecule played a role in
PVL specificity since only the galactose residue presented an axial O-4 hydroxyl in an appro-
priate position to bind to it.
The limited interaction of the galactose residue with the PVL surface was in agreement with
the limited change of affinity that was observed when comparing GlcNAcβ1-3Gal with GlcNAc
ligands. Nevertheless, the orientation of the reducing ends on the protein ring was in perfect
agreement with the strong binding to glycoconjugate surfaces. Indeed, all galactose reducing
Table 1. Determination of affinity characteristics and thermodynamic contributions for the binding of rPVL with different oligosaccharides.
glycan SPR ITC
Kd (μM) Kd (μM) n -ΔH (kJ/mol) TΔS (kJ/mol)
GlcNAc 132 124 5.0b 41.2 -18.0
GlcNAcβ1-4GlcNAc a 205 122 5.0b 36.9 -14.6
GlcNAc(β1-4GlcNAc)4 358 n.d.
GlcNAcβ1-3Gal 103 110 4.9 ± 0.2 42.1 -19.5
GlcNAcβ1-3Galβ1-4Glc (LNT2) 71 108 5.0 ± 0.2 41.7 -19.1
Biantennary N-glycan (2) (with terminal GlcNAcβ1-2Man) 179 34.4 1.9 ± 0.6 13.7 11.8
Galβ1-3GlcNAcβ1-3Galβ1-4Glc (LNT) No binding n.d.
a only one experiment by ITC
b stoichiometry value ﬁxed during ﬁtting procedure.
Standard deviation lower than 20% were obtained for ITC experiments.
doi:10.1371/journal.pone.0128190.t001
Labeling Truncated Glycans with Fungal Lectin
PLOS ONE | DOI:10.1371/journal.pone.0128190 June 4, 2015 10 / 22
ends pointed in the same direction, so that mulitantennary glycans or glycoproteins could easi-
ly display a strong multivalency effect
Several GlcNAc-transferases are upregulated in lung carcinoma
As lung carcinoma have been previously shown to express high levels of GlcNAc-terminated
glycans, we analyzed glycosyltransferase expression in transcriptomic data from 27 paired lung
adenocarinoma and adjacent “normal” tissues, available in the NCBI database [30]. We found
statistically significant variations between cancer and healthy tissues for several glycosyltrans-
ferase genes (S2 Table). In particular, expression of the GlcNAc transferases GcNT3 (one of the
GlcNAcTs responsible for the synthesis of the core 2 O-glycan structures) and B3GNT3 (re-
sponsible for the synthesis of the extended core 1 O-glycan structure) were found to be
Fig 3. Crystal structure of rPVL/GlcNAcβ1-3Gal complex. A. β-propeller fold of rPVL with the peptide chain represented as ribbon colored from blue (N-
terminal) to green (C-terminal). Disaccharides are represented as stick with 2mFo-DFc electron density maps contoured at 1 σ (0.4 ε Å-3). Calcium ions are
represented as pink sphere. B. Same propeller with solvent accessible surface of the protein. C and D, details of the interaction in site 1 with disaccharide and
water molecules. Hydrogen bonds are represented as dotted lines in panel D. All graphics have been prepared on chain A using the PyMol software
(Schrödinger).
doi:10.1371/journal.pone.0128190.g003
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markedly increased in the adenocarcinoma tissues. Those data are compatible with an increase
of the GlcNAc terminated structures in lung cancer cells.
rPVL strongly binds to GlcNAc and Neu5Ac epitopes on human cancer
cells
To examine the capacity of rPVL to recognize cells derived from human cancer tissues, lectin
staining of several cell lines was performed and quantitatively analyzed using flow cytometry.
rPVL strongly bound to cancer cells from various origins, including lung (Fig 4 and S4 Fig and
S3 Table), breast, prostate, ovary and colon carcinomas, as well as melanomas.
In the presence of 100 mMGlcNAc, the binding of rPVL to the cell lines was strongly de-
creased, indicating specific involvement of the carbohydrate binding sites (Fig 4). Interestingly,
complete inhibition was achieved only for the HBEC-3KT cell line which is an immortalized
normal lung cell line, suggesting that rPVL’s binding sites on this cell line may be of lower af-
finity than on the cancer cell lines. Since the glycan microarray showed some binding to
Neu5Ac containing glycans, sialidase treatment was performed in order to determine if
Neu5Ac-terminated cell surface glycans could be recognized by the lectin. As shown on Fig 4A,
following sialidase treatment, cell staining was almost completely lost for the HBEC-3KT cell
line, but much less so for other cell lines such as MCF-7 or A549. This result indicated that
Neu5Ac-terminated glycans represent the major rPVL ligands on the HBEC-3KT normal lung
cell line, whereas GlcNAc-terminated structures may be involved on the cancerous cell lines.
To confirm involvement of GlcNAc-terminated glycans on cancer cells such as A549 that
showed little decrease of rPVL binding following sialidase treatment, cells were grown in the
presence of 3F-Neu5Ac, an inhibitor of sialyltransferases. As a control for specificity, 2F-fu-
cose, an inhibitor of fucosyltransferases was used (Fig 5A). The latter compound did not affect
binding of either the Neu5Ac-specific lectin MAH or of rPVL. By contrast, 3F-Neu5Ac, de-
creased MAH binding by 75%, as expected, but also rPVL binding by 59%, indicating that a sig-
nificant level of rPVL binding to these cells is due to recognition of Neu5Ac epitopes.
Treatment of A549 cells by an exo ß-D-N-acetyl—hexosaminidase also resulted in a major de-
crease of rPVL binding in a dose-dependent manner, indicating that GlcNAc-terminated gly-
cans are also recognized by rPVL on this cell line. To further delineate which type of glycans
are involved, A549 cells were treated with kifunensin, an inhibitor of N-glycan maturation,
with benzyl-GalNAc, an inhibitor of O-glycosylation and with PPMP, an inhibitor of glycolipid
synthesis (Fig 5B). Treatment by all three inhibitors resulted in a decrease of the MAH
Neu5Ac-specific lectin, indicating that Neu5Ac termini are present on these three major types
of glycans. Likewise, each inhibitor decreased rPVL binding to some extent. Yet, inhibition of
rPVL binding was much clearer following benzyl-GalNAc treatment than following the other
treatments. Collectively, these data indicate that both Neu5Ac and GlcNAc present on O-gly-
cans constitute the major ligands for rPVL binding on the A549 lung carcinoma cell line.
Labeling of healthy tissues by rPVL
Labeling of healthy tissues by biotinylated rPVL was performed in the presence of either fucose
or GlcNAc to delineate specific binding. Most tissues were either not stained or only weakly
stained by the labeled lectin. When present, staining was mainly restricted to epithelial cells or
occasionally to some macrophages in the lung parenchyma and was inhibited by the presence
of 100 mMGlcNAc (Fig 6 and S4 Table). owever, a strong binding was observed on the glandu-
lar compartment of the stomach and small intestine. In this case, only a partial inhibition could
be obtained in the presence 100 mM GlcNAc, consistent with the presence of mucin presenting
terminal α-linked GlcNAc in these tissues, as previously described [5, 31].
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Fig 4. PVL binding of tumor cell lines. A. Flow cytometry histograms show rPVL-Alexa 488 binding to a lung immortalized cell line (HBEC-3KT), two lung
tumor cell lines (H358 and A549) as well as on a breast tumor cell line (MCF-7). The x axis indicates fluorescence intensity. The y axis indicates cell number.
Black line: untreated control cells; blue line rPVL-Alexa 488 5 μg ml-1 for 30 mn; red line: rPVL-alexa 488 5 μg ml-1 in the presence of GlcNAc 100 mM; green
line: rPVL-Alexa 488 5 μg ml-1 after sialidase pretreatment. B. Microscopy images of A549 NSCLC cells treated for 30 min at 37°C with 5 μg ml-1 rPVL labeled
with Alexa 488 in the presence or absence of 100 mMGlcNAc. Green channel shows rPVL-Alexa 488, blue channel shows nuclei labeled with DAPI staining.
doi:10.1371/journal.pone.0128190.g004
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Fig 5. PVL binding in the presence of glycosylation inhibitors or after treatment with glycosidases. A. Biotinylated rPVL (1 μg ml-1) or MAH (5 μg ml-1)
were incubated with A549 cells grown for 4 days in presence of DMSO (green line) or of either 400 μM 2-Fluoro-Fucose or 100 μM Fluoro-Neu5Ac (pink line).
Lectin binding was revealed by PE conjugated Streptavidin. Percentage of inhibitions are indicated according to the mean fluorescence intensities. B. Similar
experiment than in A but with A549 cells grown in the presence of 5 μMKifunensine for 4 days or in the presence of either 6 mM Benzyl-GalNAc or 10 μM
PPMP for 48h. C. Similar experiment than in A and B but with cells treated with 2.5 U (pink line) or 12.5 U ß-D-N-acetyl-hexosaminidase (blue line).
doi:10.1371/journal.pone.0128190.g005
Fig 6. PVL staining of healthy tissues. A tissue microarray (TMA) comprising healthy tissues from respiratory, digestive and genital origin was stained with
0.7 μg ml-1 rPVL-biot in presence of 0.1 M Fucose or 0.1 M GlcNAc followed by Streptavidin-HRP. AEC was used as a peroxidase substrate to reveal the
PVL staining and counterstaining was performed using hematoxylin. Slides were imaged using a NanoZoomer slide scanner with a 20x magnification. 40x
digital magnifications are also shown as insets.
doi:10.1371/journal.pone.0128190.g006
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Labeling of cancer tissues by rPVL
Since rPVL labeled various cancer cell lines, a histochemical staining of healthy and cancer tis-
sues was performed. As shown on Fig 7A a strong labeling, inhibited in the presence of
GlcNAc, was observed on colon carcinomas, whilst a weak labeling was only found on the adja-
cent normal tissue. To determine if the staining of carcinoma cells was dependent on either
Neu5Ac or GlcNAc-terminated glycans, tissue sections of canine breast carcinoma were treated
with either sialidase or exo-ß-D-N-acetyl-hexosaminidase prior to incubation with the biotiny-
lated lectin (Fig 7B). Canine breast carcinoma sections were used since they were more easily
available than human breast carcinoma sections and since the tumors are remarkably homolo-
gous to their human counterparts [32]. Both enzyme treatments led to a clear reduction of the
staining, indicating that similar to what was observed on cell lines, both Neu5Ac and GlcNAc
were involved in the lectin staining.
We next analyzed staining of various types of lung and breast carcinomas with rPVL. A clear
labeling was observed on a proportion of lung squamous cell carcinomas, and lung adenocarci-
nomas (Fig 8 and S5 Fig. The staining of cancer cells with rPVL was systematically higher than
that of the normal surrounding cells in each positive tumor sample. By contrast, none of the test-
ed bronchioalveolar, mucoepidermoid, large cell or small cell carcinomas that we tested was la-
beled, suggesting that the lectin could distinguish between distinct types of lung carcinomas.
When biotinylated rPVL was applied to breast tumor sections (Fig 9), the majority of sam-
ples appeared positive, although labeling intensity ranged from moderate to very strong. By
contrast, in normal breast tissue adjacent to the tumors, only weak staining at the apical surface
of canular epithelial cells could be occasionally observed. With the limited number of samples
available, no significant difference in staining intensity could be observed between tumors with
different HER2, hormone receptors or p53 status.
Discussion and Conclusion
The recombinant form of PVL has been produced and characterized, and its binding specificity
is different from that of other GlcNAc-binding lectins according to the specificity patterns
available from the Consortium for Functional Glycomics. Wheat germ agglutinin (WGA) and
tomato lectin (SLT) recognize terminal GlcNAc, but also bind to internal GlcNAc and to chit-
ooligosaccharides. The legume lectins from Ulex europeus (UEA-II) and Griffonia (Bandereia)
simplicifolia (GSL-II) display high specificity to truncated polylactosamine-type N-glycans
only. F17G, a lectin present on the pili of some E. coli strains, has also recently been shown to
specifically recognize terminal GlcNAcß1-3Gal motifs, although with a rather low affinity [33].
The lectin with the closest specificity pattern to PVL is AAL-2 from the mushroom Agrocybe
aegerita. This related protein (60% identity) has also been produced recombinantly and dem-
onstrated to bind to hepatoma cells and to induce apoptosis, although no information was pro-
vided on the binding event. [14].
The present work opens the route for further investigations. Although each of the six bind-
ing sites of PVL is highly specific for terminal GlcNAc, the multivalent lectin displays weak
avidity for Neu5Ac-decorated surfaces that may result in weak non-specific labeling of some
tissues. Since we aim at targeting specifically GlcNAc-terminated residues, we demonstrated
that the use of sialidase treatment and/or competition with low amounts of GlcNAc suppressed
the non-specific binding. Nevertheless, the structural knowledge of the binding sites should
allow for engineering of modified lectins with stronger selectivity.
Because of its capacity to bind to nonreducing terminal GlcNAc, rPVL is a marker of inter-
est for cancer cells, as demonstrated here, However, rPVL could also have diagnostic applica-
tions for other diseases. For example, an elderly dementia, distinct from Alzheimer disease, is
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Fig 7. PVL binds to tumor tissue with a mixed Neu5Ac and GlcNAc specificity. A. Sections from ethanol-fixed colon carcinoma and adjacent healthy
tissue from 2 different patients (# 5345 and 5378) were stained with 1 μg ml-1 rPVL-biot in presence of 0.1 M Fucose or 0.1 M GlcNAc followed by
Streptavidin-HRP. AEC was used as a peroxidase substrate to reveal the rPVL staining and counterstaining was performed using hematoxylin. Slides were
imaged using a NanoZoomer slide scanner with a 20x magnification.40x digital magnifications are also shown as insets. B. Canine breast tumor sections
(formalin fixed) were treated or not with glycosidases and then stained with 2 μg ml-1 rPVL-biot and imaged as in A.
doi:10.1371/journal.pone.0128190.g007
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related to the presence of an agalacto-N-glycan on one isoform of transferrin [34]. Also aga-
lacto-IgGs are present in the serum of patients with rheumatoid arthritis [35] and were previ-
ously detected with PVL purified from fungi [36, 37] or by use of glycosyltransferase assays
Fig 8. PVL staining of Lung tumoral tissues. A. A lung tumor TMA (formalin-fixed) was stained with 2 μg ml-1 rPVL-biot in presence of 0.1 M fucose
followed by Streptavidin-HRP. AEC was used as a peroxidase substrate to reveal the PVL staining and counterstaining was performed using hematoxylin.
Slides were imaged using a NanoZoomer slide scanner with a 20x magnification. 40x digital magnifications are also shown as insets. (Ad = adenocarcinoma;
SCC = small cell carcinoma) Representative images of the different histological tumor types are shown B. A score from 0 to 3 was attributed to each tumor,
based on the percentage of tumor cell stained and the color intensity and the staining level distribution according to tumor histological subtypes has been
represented as an histogram.
doi:10.1371/journal.pone.0128190.g008
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[38]. Some fast replicating viruses such as Ebola virus [39] and SARS coronavirus [40] were
also demonstrated to carry truncated N-glycans with exposed GlcNAc residues.
It was previously proposed that the truncated N-glycans observed on Ebola virus may be
due to their fast replication resulting in overloading of the processing machinery [39]. Such a
hypothesis could also stand for anarchically developing cancer cells for which glycosylation
could be poorly processed. However, we could demonstrate that the alterations of surface gly-
cosylation on cancer cells are correlated to modifications of glycosyltransferase expression lev-
els (S2 Table). Specific glycosylation changes may therefore occur in these cells and further
work is needed to investigate the mechanims underlying such changes of glycosylation associ-
ated with cancer.
As demonstrated in the present work, rPVL histochemical staining could be a powerful tool
to help the pathological analysis of human non-small cell lung cancers, as well as breast and
colon carcinomas. However, this will require further validation on larger cohorts of patients.
More particularly, larger scale analysis would permit to establish correlation with prognosis in
different subgroups of tumors. Other lectins were proven to be of interest, such as the Gal-
NAcβ1-3/4GlcNAc specific lectin fromWisteria japonica seeds that binds strongly to lung
squamous cell carcinoma [41]. Therefore, the further development of lectin arrays is very
promising for a better detection of glycan alterations for diagnostic purposes.
Supporting Information
S1 Fig. 1H NMR of heptasaccharide azide 2. 1H-NMR (360 MHz, D2O): δ = 5.03 (d, J1,2< 1
Hz, 1H, H-14), 4.83 (d, J1,2< 1 Hz, 1H, H-1
4´), 4.68–4.64 (m, 2H, H-11, H-13), 4.53 (d, J1,2 =
7.7 Hz, 1H, H-12), 4.47 (d, J1,2 = 8.3 Hz, 2H, H-1
5, H-15’), 4.18–4.15 (m, 1H, H-23), 4.12–4.09
Fig 9. PVL staining of breast tumoral tissues. A. A Breast tumor TMA (formalin-fixed) was stained and imaged as described in Fig 8A. Tumors were all
positive with a vast majority of cancer cells stained. Labeling intensity was estimated on a scale ranging from 1 to 4. Representative examples of tumors of
each staining level are shown. B. Staining level distributions according to tumor molecular characteristics. (HR = Hormone Receptors, TN = Triple Negative).
doi:10.1371/journal.pone.0128190.g009
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(m, 1H, H-24), 4.04–4.01 (m, 1H, H-24’), 1.99 (s, 3H, NAc), 1.97 (s, 9H, NAc).
(PDF)
S2 Fig. Thermal stability of rPVL. (A) Evolution of fluorescence of Sypro Orange binding to
denaturing rPVL at 0.5 mg ml-1 and 0.1 m. -1 () with glycan ligands. (B) Denaturation curve
derivatives. RFU: Relative Fluorescence Units.
(PDF)
S3 Fig. ITC data. Raw ITC data (top) obtained by injections of oligosaccharides in a solution
of rPVL and the respective integrated titration curve (bottom). Left, 7 mM of GlcNAcβ1-3Gal
into 0.06 mM of rPVL. Right, 9 mM of Heptasacharide in 0.1 mM of rPVL.
(PDF)
S4 Fig. Microscopy images of H358 NSCLC cells untreated or treated for 30 min at 37°C
with increasing concentrations of rPVL labelled with Alexa 488. Green channel shows
rPVL-Alexa 488, blue channel shows nuclei labelled with DAPI staining.
(PDF)
S5 Fig. rPVL labelled with biotin with paraffin-embedded tissue sections of normal human
lung (A and B) or human lung adenocarcinoma (C-F), using the streptavidin-peroxidase
technique. Sections are counterstained with hematoxylin. Left column (A, C, and E): control
without rPVL. Right column (B, D, and F): 5 μg ml-1 rPVL-treated sections. Original magnifi-
cations: x4 (A, C, D); x20 (B, E, F).
(PDF)
S1 Table. Data Collection and Refinement Statistics for rPVL- GlcNAcβ1-3Gal complex
structure.
(PDF)
S2 Table. Expression of glycosyltransferases in lung cancer. Glycosyltransferases expression
levels were extracted from a transcriptome analysis of 27 lung adenocarinoma and adjacent
normal tissues, available in the NCBI database (Su L et al., BMC Genomics 2007; GEO acces-
sion: GSE 7670), thanks to the BioGPS programme (http://biogps.org). A) Summary of the gly-
cosyltransferase expression trends in tumor versus normal tissues. A 2-sided paired t-Test was
used to check for statistical difference between the normal and cancer tissue expression (note
that the given p-values have not been corrected for multiple testing). B) Raw data. The left col-
umn corresponds to the patient identification numbers as recorded in the dataset. Data for
B3GNT 6, 7, 8, 9 and ST3GAL 3 were not available in this dataset. Note that B3GalT3 mainly
shows a GalNAc transferase activity in the Gb4Cer globoside synthesis (P antigen).
(PDF)
S3 Table. rPVL binding on various cancer cells. Binding of rPVL was determined by flow cy-
tometry on cancer cell lines from various histological origins as described in Material and
Methods. ND: not determined.
(PDF)
S4 Table. PVL staining of healthy tissues. A TMA prepared with tissues from various origins
coming from 10 different donors was stained with rPVL-biot at 0,7 μg/ml as such or in pres-
ence of 0,1 M of fucose or N-acetyglucosamine. Digestive tissues showed the strongest staining;
some of it could not be completely removed even in presence of an excess of free GlcNAc.
(PDF)
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